Objective To explore the expression of long non-coding RNA (LncRNA) KCNQ1OT1 and its clinical significance in non-small cell lung cancer (NSCLC). Methods Eighty-nine NSCLC patients who underwent surgery were recruited in Sichuan Cancer Hospital from January 2011 to December 2013. Quantitative real-time PCR was used to detect the expression of LncRNA KCNQ1OT1 in tumor tissues and paracarcinoma tissues (5cm or above away from tumor). The relationship between LncRNA KCNQ1OT1 expression and clinicopathologic features was analyzed by univariate analysis and Cox regression analysis. Results The expression of LncRNA KCNQ1OT1 significantly increased in tumor tissues than that in paracarcinoma tissues (P < 001). The patients were divided into a high expression group and a low expression group according to the relative expression of LncRNA KCNQ1OT1. Univariate analysis showed that the differences between two groups were not significant in age, gender or histological type, but were significant in tumor size (χ2=12.619, P < 001), lymph node metastasis(χ2=10.298, P=0.001), TNM stage(χ2=7.199, P=0.007), and history of smoking(χ2=24.005, P < 001). Kaplan-Meier analysis showed the patients with high LncRNA KCNQ1OT1 expression had significantly lower overall survival time (20.0 months vs. 35.0 months, χ2=45.860, P < 001) and significantly lower progression-free survival time (12.0 months vs. 24.0 months, χ2=31.510, P < 001) than those with low LncRNA KCNQ1OT1 expression. Cox regression analysis revealed that the disease stage and the expression of LncRNA KCNQ1OT1 could be used as independent prognostic markers for poor prognosis. Conclusion LncRNA KCNQ1OT1 is highly expressed in tumor tissues and associated with the prognosis of NSCLC patients, thus can be used as a potential marker for predicting the prognosis of lung cancer.
ObjectiveTo describe the research progress of long non-coding RNA (lncRNA) and gastric cancer in recent years, and to make reasonable prospect for future research direction.MethodWe collected a large amount of literatures on lncRNA and gastric cancer at home and abroad, and sort out various kinds of lncRNA, to make an in-depth interpretation of the relationship between lncRNA and gastric cancer and the mechanism of action, and then clarified the latest research progress.ResultsAt present, the molecular mechanism of the occurrence and development of gastric cancer had not been fully elucidated, but current studies had shown that lncRNA (H19, HOTTIP, UCA1, MEG3, MALAT1, HULC, HOTAIR, GAPLINC, and so on) had regulatory effects at multiple levels such as epigenetics, transcription, translation, chemoresistance, and more and more lncRNA had been discovered closely related to gastric cancer.ConclusionlncRNA is closely related to the occurrence and development of gastric cancer and may be a key target for the treatment of gastric cancer in the future.
ObjectiveThe diagnostic efficacy of long non-coding RNA (lncRNA) for tuberculosis was evaluated by systematic review. MethodsData from PubMed, Web of Science, Cochrane Library, Embase, CMJFD, CNKI and WanFang Data were searched. Literatures on the diagnostic value of lncRNA in tuberculosis from the database establishment to August 20, 2024 were selected, and the quality of literatures was assessed using QUADAS-2 tool. Meta-Disc 1.0 software tested the threshold heterogeneity of the included studies. Stata 18.0 software calculated sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and other effect sizes, and performed subgroup analysis and meta regression to explore the source of heterogeneity. Deeks funnel plot evaluates publication bias. Results A total of 28 case-control studies were included in 14 literatures. The meta-results showed that the combined sensitivity was 0.88 (95%CI 0.81 to 0.93), the specificity was 0.90 (95%CI 0.84 to 0.94), and the PLR was 9.05 (95%CI 5.16 to 15.87). The NLR and DOR were 0.13 (95%CI 0.08 to 0.22) and 67.96 (95%CI 27.27 to 169.39), and the AUC were 0.95 (95%CI 0.93 to 0.97). Subgroup analysis showed that lncRNA was more effective in the diagnosis of tuberculosis when PMBC samples, lncRNA expression was down-regulation, the study sample size was ≤100, there was cut-off value, GAPDH was used as the internal reference, and RNA extraction kit was used. meta regression indicated that lncRNA expression level and sample size were the main sources of heterogeneity. Conclusion LncRNA has high accuracy in the diagnosis of tuberculosis, and is expected to become a new biomarker to assist the diagnosis of tuberculosis.
ObjectiveThis study aimed to identify long non-coding RNAs (lncRNAs) that could serve as prognostic biomarkers for non-small cell lung cancer (NSCLC).MethodsThe Encyclopedia of RNA Interactomes (ENCORI) database was used to analyze the expression profile and RNA interaction network of lncRNA SNHG4 in NSCLC. Cell experiments were performed to determine the effects of lncRNA SNHG4 on the proliferation and migration of lung cancer cell line A549. The dual-luciferase reporter assay was employed to validate the interaction between SNHG4 and its potential targets.ResultslncRNA SNHG4 was highly expressed in NSCLC tissues. Kaplan-Meier survival analysis showed that patient survival rate was significantly correlated with SNHG4 expression levels. Knockdown of SNHG4 inhibited the proliferation, migration, and invasion of NSCLC cells while promoting cell apoptosis. Mechanistic studies identified miR-409-3p and DDX5 as direct targets of SNHG4. SNHG4 downregulated miR-409-3p expression in NSCLC cells, thereby relieving the inhibitory effect of miR-409-3p on DDX5 and promoting NSCLC cell growth. ConclusionlncRNA SNHG4 may exert its tumor-promoting role in NSCLC through the lncRNA SNHG4/miR-409-3p/DDX5 signaling pathway.
ObjectiveTo investigate the expression and clinical significance of long non-coding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and miR-199b in the peripheral blood of patients with proliferative diabetic retinopathy (PDR). MethodsA retrospective clinical study. A total of 473 patients with type 2 diabetes (T2DM) who visited Department of Ophthalmology of West China Airport Hospital of Sichuan University from February 2022 to July 2024 were included in the study. According to the diagnostic criteria for diabetic retinopathy (DR) in the Chinese Clinical Diagnosis and Treatment Guidelines for Diabetic Retinopathy, the T2DM patients were divided into three groups: the non-DR group (NDR group, 130 cases), the non-PDR group (NPDR group, 132 cases), and the PDR group (211 cases). Another 120 patients of the same age and gender who underwent simple cataract surgery during the same period were selected as the cataract group. Blood pressure, and laboratory data including fasting blood glucose (FBG), fasting insulin (FINS), glycated hemoglobin (HbA1c), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) were collected in detail for the T2DM group patients. Fasting peripheral venous blood was collected from T2DM group patients; aqueous humor was collected from 45 PDR and NPDR patients with concurrent macular edema before intravitreal injection of anti-vascular endothelial growth factor drugs. The expression levels of lncRNA MALAT1 and miR-199b mRNA in peripheral blood and aqueous humor were detected by quantitative real-time polymerase chain reaction. Receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to analyze the efficacy of lncRNA MALAT1 and miR-199b alone and in combination for predicting PDR occurrence. One-way analysis of variance was used for comparisons among multiple groups. The correlation between the expression levels of the two indicators and each clinical parameter was analyzed using Pearson correlation analysis. ResultsCompared with the NPDR group and the NDR group, the systolic blood pressure, FBG, HbA1c, FINS and TG levels of patients in the PDR group were significantly increased, while HDL-C levels were significantly decreased. The differences were statistically significant (F=42.207, 52.320, 478.335, 107.676, 86.273, 77.653; P＜0.05); the expression of peripheral blood lncRNA MALAT1 was significantly increased, while the expression of miR-199b was significantly decreased, and the differences were statistically significant (F=31.773, 152.784; P＜0.05). Compared with the NPDR group and the cataract group, the expression of lncRNA MALAT1 in the aqueous humor of patients in the PDR group was significantly increased, and the expression of miR-199b was significantly decreased (F=159.700, 114.667; P＜0.05). The correlation analysis results showed that the expression of peripheral blood lncRNA MALAT1 was positively correlated with systolic blood pressure, FBG, HbA1c, TG, and FINS (r=0.318, 0.358, 0.689, 0.474, 0.498), and negatively correlated with miR-199b (r=?0.526) and HDL-C (r=?0.489) (P＜0.05). The expression of miR-199b showed an opposite correlation with the above metabolic indicators (r=?0.419, ?0.425, ?0.712, ?0.516, ?0.541, 0.529; P＜0.05). The expression levels of lncRNA MALAT1 and miR-199b in the peripheral blood and aqueous humor of PDR patients were significantly positively correlated (r=0.732, 0.675; P＜0.05). ROC curve analysis showed that the AUC values of peripheral blood lncRNA MALAT1, miR-199b alone and in combination for predicting PDR were 0.684, 0.796, and 0.861, respectively. ConclusionsPatients with PDR exhibit high expression of lncRNA MALAT1 and low expression of miR-199b in peripheral blood. The expressions of these markers are consistent between peripheral blood and aqueous humor and are associated with glucose and lipid metabolism. Their combination demonstrates high predictive value for the occurrence of PDR.